Related references
Note: Only part of the references are listed.Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5
Karim Fizazi et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan et al.
LANCET ONCOLOGY (2015)
Androgen Receptor Expression Predicts Decreased Survival in Early Stage Triple-Negative Breast Cancer
Jung Eun Choi et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors
Geoffrey I. Shapiro et al.
CLINICAL CANCER RESEARCH (2015)
Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer
Paul J. Toren et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Phase I/II Trial of Orteronel (TAK-700)-an Investigational 17,20-Lyase Inhibitor-in Patients with Metastatic Castration-Resistant Prostate Cancer
Robert Dreicer et al.
CLINICAL CANCER RESEARCH (2014)
Complexities of androgen receptor signalling in breast cancer
Keely M. McNamara et al.
ENDOCRINE-RELATED CANCER (2014)
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
Julie C. Friedland et al.
INVESTIGATIONAL NEW DRUGS (2014)
Taxonomy of breast cancer based on normal cell phenotype predicts outcome
Sandro Santagata et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Revising the role of the androgen receptor in breast cancer
F. M. Fioretti et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2014)
Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes
Brian D. Lehmann et al.
JOURNAL OF PATHOLOGY (2014)
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
Karim Fizazi et al.
LANCET ONCOLOGY (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Selective Androgen Receptor Modulators (SARMs) Negatively Regulate Triple-Negative Breast Cancer Growth and Epithelial:Mesenchymal Stem Cell Signaling
Ramesh Narayanan et al.
PLOS ONE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
Dawn R. Cochrane et al.
BREAST CANCER RESEARCH (2014)
Targeting the molecular chaperone heat shock protein 90 (HSP90): Lessons learned and future directions
David S. Hong et al.
CANCER TREATMENT REVIEWS (2013)
Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
Hiroko Masuda et al.
CLINICAL CANCER RESEARCH (2013)
Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
Ayca Gucalp et al.
CLINICAL CANCER RESEARCH (2013)
Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers
Isabell Witzel et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
An androgen receptor N-terminal domain antagonist for treating prostate cancer
Jae-Kyung Myung et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer
Dana E. Rathkopf et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Effect of an investigational CYP17A1 inhibitor, orteronel (TAK-700), on estrogen- and corticoid-synthesis pathways in hypophysectomized female rats and on the serum estradiol levels in female cynomolgus monkeys
Masuo Yamaoka et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2013)
Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression In Vivo
Christian Thomas et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Biochemical and Objective Response to Abiraterone Acetate Withdrawal: Incidence and Clinical Relevance of a New Scenario for Castration-resistant Prostate Cancer
Orazio Caffo et al.
UROLOGY (2013)
Overcoming mutation-based resistance to antiandrogens with rational drug design
Minna D. Balbas et al.
ELIFE (2013)
Differential impact of the expression of the androgen receptor by age in estrogen receptor-positive breast cancer
Eriko Tokunaga et al.
CANCER MEDICINE (2013)
Androgen receptor expression predicts breast cancer survival: the role of genetic and epigenetic events
Kate M. Peters et al.
BMC CANCER (2012)
Clinicopathologic Features, Patterns of Recurrence, and Survival Among Women With Triple-Negative Breast Cancer in the National Comprehensive Cancer Network
Nancy U. Lin et al.
CANCER (2012)
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Nicola J. Clegg et al.
CANCER RESEARCH (2012)
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim Fizazi et al.
LANCET ONCOLOGY (2012)
The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer
Dabei Tang et al.
MEDICAL ONCOLOGY (2012)
Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray
Jiehua He et al.
MEDICAL ONCOLOGY (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Abiraterone Acetate Withdrawal Syndrome: Does It Exist?
Helene Gauthier et al.
CASE REPORTS IN ONCOLOGY (2012)
Mechanism of Androgen Receptor Antagonism by Bicalutamide in the Treatment of Prostate Cancer
D. J. Osguthorpe et al.
BIOCHEMISTRY (2011)
Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy
Sibylle Loibl et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer
Min Ni et al.
CANCER CELL (2011)
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
Brett S. Carver et al.
CANCER CELL (2011)
Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women
Rong Hu et al.
CLINICAL CANCER RESEARCH (2011)
TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate
Daniel C. Danila et al.
EUROPEAN UROLOGY (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study
Laura C. Collins et al.
MODERN PATHOLOGY (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Expression of androgen receptors in primary breast cancer
S. Park et al.
ANNALS OF ONCOLOGY (2010)
Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells
Francesca De Amicis et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers
Isabella Castellano et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
Raymond J. Andersen et al.
CANCER CELL (2010)
Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with hormone responsive advanced breast cancer: no evidence of a pharmacokinetic interaction between exemestane and fulvestrant.
E Mrozek et al.
CANCER RESEARCH (2010)
Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation
Leo A. Niemeier et al.
MODERN PATHOLOGY (2010)
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
Howard I. Scher et al.
LANCET (2010)
HSP90 at the hub of protein homeostasis: emerging mechanistic insights
Mikko Taipale et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
Philip A. Watson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers
Donata Micello et al.
VIRCHOWS ARCHIV (2010)
Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk
Joanne F. Dorgan et al.
BREAST CANCER RESEARCH (2010)
Increased Expression of Androgen Receptor Sensitizes Prostate Cancer Cells to Low Levels of Androgens
Kati K. Waltering et al.
CANCER RESEARCH (2009)
Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer
Gerhardt Attard et al.
CANCER RESEARCH (2009)
Fluorescence In situ Hybridization Analysis of Circulating Tumor Cells in Metastatic Prostate Cancer
Margaret A. Leversha et al.
CLINICAL CANCER RESEARCH (2009)
Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer
Ana M. Gonzalez-Angulo et al.
CLINICAL CANCER RESEARCH (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Androgens and the breast
Constantine Dimitrakakis et al.
BREAST CANCER RESEARCH (2009)
Antiandrogen withdrawal in castrate-refractory prostate cancer
A. Oliver Sartor et al.
CANCER (2008)
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer
Jennifer A. Locke et al.
CANCER RESEARCH (2008)
Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
R. Bruce Montgomery et al.
CANCER RESEARCH (2008)
Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers
Yoshinari Ogawa et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer
Elahe A. Mostaghel et al.
CANCER RESEARCH (2007)
Androgen receptor amplification is associated with increased cell proliferation in prostate cancer
Kyllikki Haapala et al.
HUMAN PATHOLOGY (2007)
An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen
A. S. Doane et al.
ONCOGENE (2006)
Endogenous steroid hormone concentrations and risk of breast cancer: Does the association vary by a woman's predicted breast cancer risk?
AH Eliassen et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer
M Stanbrough et al.
CANCER RESEARCH (2006)
Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer
MA Titus et al.
CLINICAL CANCER RESEARCH (2005)
Identification of molecular apocrine breast tumours by microarray analysis
P Farmer et al.
ONCOGENE (2005)
Androgenic induction of growth and differentiation in the rodent uterus involves the modulation of estrogen-regulated genetic pathways
PV Nantermet et al.
ENDOCRINOLOGY (2005)
Androgen receptor in prostate cancer
CA Heinlein et al.
ENDOCRINE REVIEWS (2004)
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583)
EJ Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance
J Holzbeierlein et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Molecular determinants of resistance to antiandrogen therapy
CD Chen et al.
NATURE MEDICINE (2004)
Androgen receptor gene amplification and protein expression in recurrent prostate cancer
OH Ford et al.
JOURNAL OF UROLOGY (2003)
Androgen receptor expression in estrogen receptor-negative breast cancer - Immunohistochemical, clinical, and prognostic associations
SN Agoff et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2003)
Recent advances in androgen receptor action
HJ Lee et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2003)
Androgen receptor mutations in androgen-in dependent prostate cancer: Cancer and Leukemia Group B Study 9663
ME Taplin et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma
DJ Samson et al.
CANCER (2002)
Molecular biology of the androgen receptor
EP Gelmann
JOURNAL OF CLINICAL ONCOLOGY (2002)
High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: A renewed role for adrenalectomy
KT Morris et al.
SURGERY (2001)
Interactions between androgen and estrogen receptors and the effects on their transactivational properties
V Panet-Raymond et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2000)
Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor
XY Zhao et al.
NATURE MEDICINE (2000)
Clinical states in prostate cancer: Toward a dynamic model of disease progression
HI Scher et al.
UROLOGY (2000)
Share Paper
